Autopsy report · NCT02905994

Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia

“Funding Withdrawn”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Massachusetts General Hospital

Sponsor type

University, hospital or other

Conditions

AML

Interventions

Volasertib; Cytarabine; Idarubicin; Bone Marrow Biopsy

Participants

0

Sites

2

Countries

United States

Trials that died the same way

• Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
  “funding was withdrawn” (96% match in meaning)
• Hydroxychloroquine Efficacy in Chronic Urticaria
  “withdrawn, not funded” (92% match in meaning)
• Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
  “Funding withdrawal” (90% match in meaning)
• Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
  “Withdrawal of funding” (90% match in meaning)
• The Effects of Sapropterin Dihydrochloride Supplementation on in Vivo Redox Status in Patients With Classical PKU
  “Withdrawn due to no funding” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.